Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(15)00415-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines.
NPJ Vaccines
December 2022
Department of Microbiology and Immunology, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA.
In recent years, tattooing technology has shown promising results toward evaluating vaccines in both animal models and humans. However, this technology has some limitations due to variability of experimental evaluations or operator procedures. The current study evaluated a device (intradermal oscillating needle array injection device: IONAID) capable of microinjecting a controlled dose of any aqueous vaccine into the intradermal space.
View Article and Find Full Text PDFEbola virus disease outbreak in the Democratic Republic of the Congo: A mini-review.
Ann Med Surg (Lond)
August 2022
Standing Committee of Research and Exchange, Medical Student Association, D.R., Congo.
Ebola virus disease is one of the most serious and deadliest infectious diseases in the world with a sufficient number of recorded deaths. Since its discovery in 1976 until its last epidemic (14th), recorded and declared on April 23, 2022 by the National Minister of Public Health of the Democratic Republic of Congo and we have observed a succession of simultaneous epidemics of the disease to Ebola virus. This disease escapes the control of the health system of the Democratic Republic of the Congo, a health system which is already destabilized by the corona virus disease 2019 pandemic.
View Article and Find Full Text PDFDiscovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
Eur J Med Chem
October 2022
State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, 1 Xiangshanzhi Road, Hangzhou, 310024, China. Electronic address:
Ebola virus (EBOV), one member of the family Filoviridae, can causes hemorrhagic fever and other severe diseases in humans with a high mortality rate (25-90%). Until recently, there were no approved drugs and very limited treatment method for Ebola virus disease. In this study, we discovered a series of potent Ebola entry inhibitors with the (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl)decahydroisoquinoline-3-carboxamide scaffold from high-throughput screening in reported pseudotyped virus system.
View Article and Find Full Text PDFCOVID-19 in Africa: the little we know and the lot we ignore.
Epidemiol Prev
January 2021
Former Mozambique Public Health System.
COVID has stirred up an information deluge that challenges our capacity to absorb and make sense of data. In this unrelenting flow of information, Africa has been largely off the radar, escaping the attention of the scientific literature and the media. International agencies have been the exception: despite the still low numbers of cases and deaths, they have voiced concerns, often in catastrophic terms, on the health, economic and social impacts of COVID in African countries.
View Article and Find Full Text PDFExploiting Pre-Existing CD4 T Cell Help from Bacille Calmette-Guérin Vaccination to Improve Antiviral Antibody Responses.
J Immunol
July 2020
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461;
The continuing emergence of viral pathogens and their rapid spread into heavily populated areas around the world underscore the urgency for development of highly effective vaccines to generate protective antiviral Ab responses. Many established and newly emerging viral pathogens, including HIV and Ebola viruses, are most prevalent in regions of the world in which infection remains endemic and vaccination at birth with bacille Calmette-Guérin (BCG) is widely used. We have investigated the potential for using CD4 T cells arising in response to BCG as a source of help for driving Ab responses against viral vaccines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!